Profusa Secures Exclusive Know-How License with Mayo Clinic for Oxygen Monitoring Technology
PFSA is trading near its 52-week low of $1.88 (2.7% above the low).
Summary
Profusa has entered into a material know-how license agreement with Mayo Clinic, granting exclusive rights to patent and know-how for its Lumee oxygen monitoring technology in critical medical fields.
Key Events · M&A and Partnerships · PFSA
-
Strategic Partnership with Mayo Clinic
Profusa, Inc. entered into a know-how license agreement with Mayo Foundation for Medical Education and Research, a highly reputable medical institution, on February 11, 2026.
-
Exclusive License for Key Technology
The agreement grants Profusa an exclusive, worldwide license to certain patent rights and a non-exclusive license to related know-how for continuous oxygen measurement tools and Critical Limb-Threatening Ischemia (CLTI), including its Lumee product.
-
Accelerates Product Development and Commercialization
The collaboration aims to accelerate regulatory approval and commercialization of Profusa's Lumee technology and develop new tethered continuous oxygen monitoring products for high-impact clinical applications.
-
Financial Terms Include Royalties and Milestones
The agreement includes provisions for royalties on net sales of licensed products, milestone payments upon development and commercialization events, and a share of sublicense income.
Analysis · PFSA · Industrial Applications And Services
This agreement with Mayo Foundation for Medical Education and Research is a significant strategic development for Profusa, providing a crucial positive catalyst following a series of highly dilutive financing activities and a reverse stock split in recent days. The exclusive, worldwide license for patent rights and non-exclusive license for know-how in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI) validates Profusa's Lumee product and expands its potential market reach. While specific financial terms are redacted, the partnership with a highly reputable institution like Mayo Clinic provides a strong positive signal for the company's technology and commercialization efforts, potentially improving investor sentiment and long-term prospects as the stock trades near its 52-week low.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 43.9% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PFSA was trading at $1.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $1.88 to $975.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.